Opinion|Videos|July 12, 2024
Expert Perspectives: Sequencing Approaches with CAR-T and Bispecifics in R/R MM
The expert panel shares clinical insights on sequencing CAR T-cell therapies and bispecific antibodies for patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please comment on the recent updates from MagnetisMM-32 investigating elranatamab vs EPd, PVd, or Kd.
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
2
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
3
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
4
Neoadjuvant BOT + BAL Yields Pathologic Responses in pMMR/dMMR Colon Cancer
5